DBPIA-NURIMEDIA

Transcription

1 Printed in the Republic of Korea "/"-:5*$"- 4$*&/$& 5&$)/0-0(: Vol. 20, No. 2, , $.4.4 w x q p š ³ Á Áw Á Á Á 1 g ( ), 2 ( ) w wq, 3 w w w Sensitive determination of paroxetine in canine plasma by liquid chromatography-tandem mass spectrometry (LC-MS/MS) Kyu Young Chang 1, Seung Woo Kang 1,3, Sang Beom Han 3, Jeong-Rok Youm 3, Kyung Ryul Lee 1,2 G and Hee Joo Lee 1,2 1 Dept. of Drug Development Supporting Service. BioCore Co., Ltd., 108-1, Yangjea-dong, Seocho-gu, Seoul, , Korea 2 Dept. of Pharmacokinetics, Seoul Medical Science Institute, Seoul Clinical Laboratory, 7-14, Dongbinggo-dong, Yongsan-gu, Seoul, , Korea 3 College of Pharmacy, Chung-Ang University, 221, Huksuk-dong, Dongjak-gu, Seoul, , Korea (Received November 7, 2006; Accepted February 27, 2007) : x q p (LLE) wš j m v-k»(lc-ms/ms) w w w. q p ü t w v p TBME(tert-butyl methyl ether) wš d w k z, 100 µl w LC-MS/MS w. HPLC Capcell Pak UG120( mm, 5 µm) f w, 50% m p (ph 3, formic acid ) w š, 0.2 ml/min w. MS/MS SRM(selective reaction monitoring) q p v p, ƒƒ m/z , m/z w 0.02~5 ng/ml (R 2 ) ùkü. w w 0.02 ng/ml, ü ƒ 7.67 % w š, y 92.96~ % x q p w w p,, y š y w. Abstract: A simple and sensitive method for the determination of paroxetine in canine plasma was developed and validated by liquid-liquid extraction and liquid chromatography-tandem mass spectrometry (LC-/MS/MS). Fluoxetine was used as an internal standard. Paroxetine and internal standard in plasma samples were extracted using TBME (tert-butyl methyl ether). A centrifuged upper layer was then evaporated and reconstituted with Corresponding author Phone : +82-(0) Fax : +82-(0) heejoolee0@yahoo.co.kr 138

2 ³ Á Áw Á Á Á 139 mobile phase of 50% acetonitrile adjusted to ph 3 by formic acid. The reconstituted samples were injected into a Capcell Pak UG120 ( mm, 5 µm) column. Using MS/MS with SRM (selective reaction monitoring) mode, the transitions (precursor to product) monitored were m/z for paroxetine, and m/z for internal standard. Linear detection responses were obtained for paroxetine concentration range of ng/ml. A correlation coefficient of linear regression (R 2 ) was Detection of paroxetine in canine plasma was accurate and precise, with limit of quantification at 0.02 ng/ml. The method has been successfully applied to pharmacokinetic study of paroxetine in healthy beagle dogs. Key words : Paroxetine, LC-MS/MS, canine plasma, pharmacokinetic study q p(paroxetine) (3S-trans)-3-[(1,3-benzodioxol- 5-yl-oxy)methyl]-4-(4-fluorophenyl)piperidine yw (Fig. 1) ƒ, w xk y,, œy, z zœs, h e š. q p m k w (selective serotonin re-uptake inhibitor, SSRI), 1-4 y w z w m y yw Fig. 1. Chemical structures of (A) paroxetine, (B) fluoxetine (I.S.). k w» m y 5-9. w wg x ùkù š, yz (monoamine oxidase inhibitors, MAOIs) y» ƒ š 5-9. q p šx 3~8, x» 15~22 š, x 2, mw š. 10 q p j m v(hplc) 11-14» j m v(gc) w. j m v q p y w š xÿ»» w dansyl chloride y w xÿ» w š. w w ƒ 5 ng/ml w w» ƒ û, ƒ ƒ š x w ƒ 0.2 ng/ml w. 12 j m v-»(lc-ms) j m v-k» (LC-MS/MS, triple quadrupole ion trap ) w x q p š š š, š (solid phase extraction, SPE) - (liquid-liquid extraction, LLE). ù j m v-» w w (limit of quantitation, LOQ) ƒ x 0.05~5 ng/ml 100 j š. q p š w» w, - (LLE) j m v-k»(lc-ms/ms) Vol. 20, No. 2, 2007

3 140 LC-MS/MS w x q p š w š w û w, FDA ƒ w (validation) w. w, q p n w x wš, w x q p w, w w. x»» q p(paroxetine) ü t w v p(fluoxetine) Sigma (St. Louis, MO, USA) qt w. w m p, s, k Fisher Scientific (Springfield, NJ, USA) HPLC w w, w TBME (tert-butyl methyl ether)»k p 1 w. HPLC Thermo Finnigan Surveyor HPLC (Thermo Electron Co., San Jose, CA, USA), w autosampler CTC ANALYTICS PAL (Zwingen, Switzerland), k»(ms/ms) TSQ Quantum Ultra (Thermo Electron Co., San Jose, CA, USA) w. w MS/MS collision cell o 90 {, y (S/N ratio) j š w š. HPLC f Shiseido Capcell Pak UG120(2.0 Ü 150 mm, 5 µm, Shiseido, Tokyo, Japan) w, f y w ChemTech Korea (Seoul, Korea) stainless steel frit wx(0.5 µm) w. l e Thermo Electron Xcalibur (Ver. 1.4) w. t q p t t 50% k 1 mg/mlƒ w z, þ w œx w x q p ƒ ƒƒ 0.02, 0.05, 0.1, 0.2, 0.5, 1, 2 5 ng/ml ƒ t x. w ü t v p 50 % k 1 mg/ mlƒ wš, 50 % k w 100 ng/mlƒ w z, Ÿw 4 o C w. t x 0.3 ml x š» ü t v p 20 µl ƒw š k yw» 10 yww.» TBME(tert-butyl methyl ether) 1.5 ml š k» 15 w. 13,000 rpm 2 w z, x þ š d þ g. d k, d» d w Áòw x»š 40 C o» g. ƒ z, 100 µl ƒw w k, 13,000 rpm 5 w. Áòw d w z, 20 µl LC-MS/MS w.» ü t vj w q p vj ƒ š w. -$.4.4 y x q p š LC-MS/MS š19w y w z ww. x w. f w Shiseido Capcell Pak UG120(2.0Ü150 mm, 5 µm, Shiseido, Tokyo, Japan) w, f y w stainless steel frit wx(0.5 µm) w. 50 % m p w z,» s ƒw ph 3.0 wš, 0.2 µm membrane filter wš, q» ƒ w w. f 40 C w o w š, 0.2 ml/min w w. w MS/MS, y ESI(electrospray ionization) kw, positive ion mode SRM(selected reaction monitoring) w. Nebulizing gas ƒ, collision gas šƒ w š,»k MS/ MS q l spray voltage 5 kv, sheath gas pressure 20, aux gas pressure 10, capillary temp. 320 o C, tube lens offset 78(I.S. 70), collision pressure 1.2 mtorr, collision energy 20(I.S. 10) w y w. q p ü t w v p (precursor ion) ƒƒ m/z 330, 310 y ([M+H] ) + w, (precursor ion) m/z 192, 148 ƒƒ l w. w x 5z ww ü x y w š, 5 x ww Analytical Science & Technology

4 ³ Á Áw Á Á Á 141 x w. x yw 6 q p 16 mg/kg n w z, ƒ w w 70 C w x e o w š 3 kw 0.3 ml w w w. w LC-MS/MS w j m l ü t vj w q p vj wš, w w x q p w. š x q p q p ü t v p positive ion mode y ([M+H] ) + m/z 330 (Fig. 2) m/z 310 (Fig. 3) ƒ w», ƒ w. p q p [M+H] + m. w w product ion scan w, q p m/z 192, 178, 151, 135, 123, 109, 70 š, v p m/z 148.»ƒ ƒ j q p m/z 192 Fig. 2. Representative electrospray spectra of (A) Q1 mass spectrum of paroxetine, (B) product ion spectrum for the [M+H] + molecule of paroxetine. Vol. 20, No. 2, 2007

5 142 LC-MS/MS w x q p š Fig. 3. Representative electrospray spectra of (A) Q1 mass spectrum of fluoxetine, (B) product ion spectrum for the [M+H] + molecule of fluoxetine. v p m/z 148 w. q p v p ion transition m/z , m/z w SRM w, ƒ ùkü. w œx œx q p ü t wì ƒw q p n w z 2 z w x x w z, LC-MS/MS w j m Fig. 4 Fig. 5 ùkü. q p vj 1.8, ü t v p vj 2.0, 2.6. MS/MS k œx q p v p vj w vj, vj k yw. œx, œx ü t ƒw 0.02, 0.05, 0.1, 0.2, 0.5, 1, 2, 5 ng/ml t x ƒƒ w z LC-MS/MS w, x l w q p Y(q p/ü t vj ) = X(q p, ng/ml) (R =0.9993) ~5 ng/ml yw ùkü (Fig. 6). x q p w (LLOQ, lower limit of quantitation) j m y (S/N ratio) 10 wš 20% w š, y 80~120 % w 0.02 ng/ Analytical Science & Technology

6 ³ Á Áw Á Á Á 143 Fig. 4. LC-MS/MS chromatograms of (A) blank canine plasma, (B) blank canine plasma spiked with paroxetine and internal standard (1 ng/ml as paroxetine). ml w. ƒ» 4ƒ (0.02, 0.2, 1 5 ng/ml) q p t x w, (C.V., %) ü 2.12~5.66 %, 3.15~7.67% ù kûš, y 92.96~ % ùkû (Table 1), mw q p z 75.2~82.6 %. l x q p w LC-MS/MS w x w p,, y š. y q p w kƒ yw 6 q p (REFERENCE) x (TEST) 16 mg/ kg n w z, ƒ l x w. q p sw x -70 o C w z, w w t x w wš LC-MS/MS w. x x w q p - š Fig. 7 ùkü. Vol. 20, No. 2, 2007

7 144 LC-MS/MS w x q p š Fig. 5. LC-MS/MS chromatograms of canine plasma sample at 2 h after oral administration of paroxetine tablets (16 mg/kg). Fig. 6. Calibration curve of paroxetine in canine plasma (y = x , R 2 = ). Table 1. Precision and accuracy for the LC-MS/MS analysis of paroxetine in canine plasma Conc. (ng/ml) Precision (C.V., %) Intraday Interday Accuracy a (%) Û Û Û Û1.97 a : Mean Û SD (n = 5) š x q p w 2000 HPLC (UV), x Ÿ»(FLD) w ƒ. ƒ ƒ xÿ» w w ƒ 0.2 ng/ml 12 w. w š vjƒ e ƒ w, w p w w w ƒ w. 1 10~20 y y. x t w ww» w ~ Analytical Science & Technology

8 ³ Á Áw Á Á Á 145 Fig. 7. Mean plasma concentration-time profile of paroxetine after oral administration of paroxetine tablets (16 mg/kg). Bars represent standard deviation of the mean (n = 3). w, š HPLC-UV, HPLC-FLD ww» k ¼ ƒ w. w w» w 2000 l LC-MS LC-MS/MS w t y w w, q p w LC-MS, LC-MS/MS(triple quadrupole ion trap ) w š. Juan 17 plasma 0.5 ml LC-MS(single quadrupole) w w 5 ng/ml, Segura 18 plasma 1 ml ion trap LC-MS/MS w w 0.7 ng/ml, Zhu 19 plasma 0.5 ml triple quadrupole LC-MS/MS w w 0.2 ng/ml, Naidong 20 plasma 0.4 ml triple quadrupole LC-MS/MS w w 0.05 ng/ml, Massaroti 21 plasma 0.5 ml triple quadrupole LC-MS/ MS w w 0.2 ng/ml šw š q p w x ww. w plasma 0.3 ml w w 0.02 ng/ml» š w yw. TBME(tert-butyl methyl ether) w - (LLE) k (LC-MS/MS) w x q p w. t x l w 0.02~5 ng/ml (R 2 ) yw. ü 2.12~5.66 %, 3.15~7.67 %, y 92.96~ % w w y š w. w,» š w g w 0.02 ng/ml¾ û q p» ¾ x q p d w. x q p w w, wz x. š x 1. G. C. Dunbar, J. B. Cohn, L. F. Fabre, J. P. Feighner, R. Vol. 20, No. 2, 2007

9 146 LC-MS/MS w x q p š R. Fieve, J. Mendels and R. K. Shrivastava, Br. J. Psychiatry, 159, (1991). 2. C. G. Gottfries, I. Karlsson and A. L. Nyth, Int. Clin. Psychopharmacol, 6, (1992). 3. S. M. Holliday and G. L. Plosker, Drugs Aging, (1993). 4. R. Lane, D. Baldwin and S. Preskom, J. Psychopharmacol, 9, 5-11 (1995). 5. D. K. Raap and L. D. Van de Kar, Life Sci, 65, (1999). 6. Y. Zhang, D. K. Raap, F. Garcia, F. Serres, Q. Ma, G. Battaglia and L. D. Van de Kar, Brain Res, 855, (2000). 7. B. Rodriguez de la Torre, J. Dreher, I. Malevany, M. Bagli, M. Kolbinger, H. Omran, B. Luderitz and M. L. Rao, Ther. Drug. Monit. 23, (2001). 8. C. Duverneuil, G. L. de la Grandmaison, P. de Mazancourt and J. C. Alvarez, Ther. Drug. Monit. 25, (2003). 9. K. Titier, N. Castaing, E. Scotto-Gomez, F. Pehourcq, N. Moore and M. Molimard, Ther. Drug. Monit, 25, (2003). 10. C. Hiemke and S. Hrtter, Pharmacol. and Ther., 85, (2000). 11. J. P. Foglia, D. Sorisio, M. Kirshner and B. G. Pollock, J. Chromatogr. B, 693, (1997). 12. J. G. Shin, K. A. Kim, Y. R. Yoon, I. J. Cha, Y. H. Kim and S. G. Shin, J. Chromatogr. B, 713, (1998). 13. C. Lpez-Calull and N. Dominguez, J. Chromatogr. B, 724, (1999). 14. I. A. Zainaghi, V. L. Lanchote and R. H. C. Queiroz, Pharmacol. Res., 48, (2003). 15. C. T. Lai, E. S. Gorden, S. H. Kennedy, A. N. Bateson, R. T. Coutts and G. B. Baker, J. Chromatogr. B, 749, (2000). 16. H. J. Leis, W. Windischhofer and G. Fauler, J. Chromatogr. B, 779, (2002). 17. H. Juan, Z. Zhiling and L. Huande, J. Chromatogr. B, 820, (2005). 18. M. Segura, J. Ortuno, M. Farre, R. Pacifici, S. Pichini, J. Joglar and J. Segura, Rapid Commun. Mass Spectrom., 17, (2003). 19. Z. Zhu and L. Neirinck, J Chromatogr. B Analyt Technol. Biomed. Life Sci., 780, (2002). 20. W. Naidong and A. Eerkes, Biomed. Chromatogr., 18, (2004). 21. P. Massaroti, N. M. Cassiano, L. F. Duarte, D.R. Campos, M. A. M. Marchioretto, G. Bernasconi, S. Calafatti, F. A. P. Barros, E. C. Meurer and J. Pedrazzoli, J. Pharm. Pharmaceut. Sci., 8, (2005). Analytical Science & Technology